Dutch reimbursement authority suggests Roche's off-label Avastin for wet AMD instead of Novartis' Lucentis
This article was originally published in Scrip
The Dutch government is currently mulling whether or not to follow a recommendation from the CVZ, which gives advice on which treatments health insurers should fund, to "conditionally delist" Novartis' Lucentis (ranibizumab) as a second-line treatment for wet AMD, behind off-label Avastin (Roche's bevacizumab).
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.